Sign up for news updates

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

ILCN Lung Cancer News

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

2020

Add ILCN as a preferred source
  • Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

    Lorlatinib in ROS1-Positive NSCLC: A Review of Recent Data

    Systemic, Targeted, & Immune Therapies

    By Ben Solomon, MBBS, PhD, FRACP Posted: August 21, 2020 ROS1 rearrangements are found in 1% to 2% of patients with NSCLC. They tend to occur in never smokers and those with adenocarcinoma histology, but molecular testing guidelines recommend testing all patients with non-squamous NSCLC for ROS1 rearrangements regardless of smoking history. Crizotinib was the…

  • IASLC Journals Share Exciting Milestones on Metrics Journeys

    IASLC Journals Share Exciting Milestones on Metrics Journeys

    Society News

    By Joy Curzio Posted: August 21, 2020 The Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC), has a 2019 impact factor of 13.357, an increase from 12.460 in 2018. Th is moves the journal’s rank to 3rd out of 64 respiratory medicine journals and…

  • Telehealth: Bridging the Digital Divide Is Still a Work In Progress

    Telehealth: Bridging the Digital Divide Is Still a Work In Progress

    Evolving Standards of Care

    By Sandip Pravin Patel, MD, and Martin Edelman, MD Posted: August 21, 2020 Dr. Sandip Pravin Patel Dr. Martin Edelman                       COVID-19 has drastically affected medicine and broader society. With physical distancing necessitating the need to overcome limitations in prevention and treatment, telehealth has become…

  • Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

    Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC

    Evolving Standards of Care, Systemic, Targeted, & Immune Therapies

    By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD Posted: August 21, 2020 Immune checkpoint inhibitors (CPIs) have revolutionized the treatment of metastatic NSCLC. However, approximately 20% to 30% of patients with metastatic NSCLC have an oncogene-driven disease, for which targeted therapies with mutation-specific tyrosine kinase inhibitors (TKIs) are…

  • Smoking Cessation After Cancer Diagnosis: A Neglected Problem

    Smoking Cessation After Cancer Diagnosis: A Neglected Problem

    Lung Cancer Risk Reduction & Prevention

    By Jacek Jassem, MD, PhD, and Carolyn Dresler, MD, MPA Posted: August 21, 2020 The world is currently overwhelmed with cases of the novel virus COVID-19 and its devastating death toll. We acknowledge that finding a treatment, cure, and vaccine is currently our nations’ first responsibility. Amidst this, however, all of our underlying diseases continue…

  • Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

    Pembrolizumab Considered for Second Tissue-Agnostic Cancer Indication

    Regulatory Agency Perspective

    By Erik MacLaren, PhD Posted: August 21, 2020 The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Merck’s immune checkpoint inhibitor pembrolizumab, adding a new tissue-agnostic indication for patients, including children, who have solid tumors with a tumor mutational burden (TMB) of 10 or more mutations per megabase of DNA.1 The new…

  • Bringing Telehealth to the Front Lines of Lung Cancer Care in the COVID-19 Pandemic

    Bringing Telehealth to the Front Lines of Lung Cancer Care in the COVID-19 Pandemic

    Evolving Standards of Care

    By Luis E. Raez, MD, FACP, FCCP Posted: August 21, 2020 Our current electronic medical records (EMR) are equipped with telehealth capability. Some of us have spent the last 2 to 3 years working on the implementation of this field in our cancer practices. However, during that time, the enthusiasm from doctors and patients was…

  • Conducting a Lung Multidisciplinary Tumor Board at the National University Cancer Institute, Singapore

    Conducting a Lung Multidisciplinary Tumor Board at the National University Cancer Institute, Singapore

    Evolving Standards of Care

    By Ross Soo, MB, BS, PhD, FRACP Posted: August 21, 2020     Dr. Ross Soo Impressive progress has been achieved in many aspects of lung cancer. Over the past decade, advances have occurred in multiple areas including diagnostic radiology, interventional pulmonology and radiology, molecular pathology, radiation therapy, minimally invasive surgery, immunotherapy and molecular-targeted therapy.…

  • Patient Perspectives on Telehealth During COVID-19: Balancing Fear, Self-Advocacy

    Patient Perspectives on Telehealth During COVID-19: Balancing Fear, Self-Advocacy

    Evolving Standards of Care

    By Jennifer Byrne Posted: August 21, 2020 For nearly 2 decades, Bonnie Anderson has defied incredible odds in the face of mesothelioma, hairy cell leukemia, breast cancer, lung cancer, and kidney cancer. “Since they can’t do anything about the mesothelioma or the kidneys or any of the tumors, I’m pretty much out of options until…

  • Potential Improvement in Lung Cancer Deaths and Overall Mortality With Integration of Smoking Cessation and Lung Cancer Screening

    Potential Improvement in Lung Cancer Deaths and Overall Mortality With Integration of Smoking Cessation and Lung Cancer Screening

    Lung Cancer Risk Reduction & Prevention

    By Lawson Eng, MD, FRCPC, and William K. Evans, MD, FRCPC Posted: August 21, 2020 IN REFERENCE TO: Cao P, Jeon J, Levy DT, et al. Potential impact of cessation interventions at the point of lung cancer screening on lung cancer and overall mortality in the United States. J Thorac Oncol. 2020. [Epub ahead of…

View ILCN Archives

Provider Resources

Popular Articles